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ABSTRACTS / RE´SUME´S
Oral administration of lactoferrin enhances viral
decline in patients with genotype-1B-related
chronic hepatitis C treated with Peginterferon a-
2B plus ribavirin
N. Kumagai, S. Tsunematsu, H. Hamano, K. Yamauchi, and K. Tsuchimoto
Research Center for Liver Diseases, Kitasato Institute Hospital, Tokyo, Japan; Nutritional
Science Laboratory, Morinaga Milk Industry Co. Ltd, Zama, Japan
We previously reported that lactoferrin (Lf) lowers serum
HCV-RNA levels in patients with genotype-1b-related
chronic hepatitis C and that pre-administration of Lf im-
proves the clinical outcome of treatment with interferon
(IFN) plus ribavirin in patients with chronic hepatitis C.
Here, to evaluate the efficacy of Lf on viral kinetics, we
studied HCV dynamics in patients with genotype 1b and a
high viral load who were randomly assigned to the follow-
ing 2 different treatment groups: (i) combination therapy in-
volving Peginterferon a-2b plus ribavirin (Peg-R);
(ii) combination therapy (Peg-R) plus oral administration of
Lf at a dose of 600 mg/day (Peg-R-Lf).
Patient baseline characteristics between the Peg-R group
(n = 11) and the Peg-R-Lf group (n = 9) were similar.
Mean serum HCV-RNA levels at baseline in the Peg-R and
Peg-R-Lf groups were 1500 KIU/mL and 1468KIU/mL, re-
spectively. Undetectable HCV-RNA in serum at 12 weeks
post-treatment was observed more frequently in the Peg-R-
Lf group (4/6) than in the Peg-R group (3/10), although
this difference was not statistically significant. Using a log-
transformed linear regression model, the decline slope was
calculated on serum HCV-RNA quantifications. As a result,
early phase of viral decay (weeks 0–12) was significantly
faster in the Peg-R-Lf group compared with those with
Peg-R group.
In the Peginterferon plus ribavirin treatment, most patients
with early viral response (EVR) defined at week 12 as an at
least 2-log decline from baseline of the HCV-RNA level
subsequently achieved a sustained viral response (SVR).
Our results suggest that Lf enhanced antiviral effect in the
early phase of HCV dynamics and helped EVR for the Pe-
ginterferon plus ribavirin treatment in patients with chronic
hepatitis C.
Oral administration of lactoferrin raises NK cell
activity in mice
T. Kuhara, K. Yamauchi, and M. Takase
Nutritional Science laboratory, Morinaga Milk Industry Co. Ltd, Japan
There have been numerous studies indicating that lacto-
ferrin (LF) influences various immune functions. Recently,
some reports have shown that bovine LF (bLF) enhanced
anti-microbial and anti-tumor immune activities when orally
administered. We observed that oral bLF administration for
7 consecutive days augmented the population and number of
natural killer (NK) cells in peripheral blood and spleen in a
dose-dependent manner, and enhanced interferon-g produc-
tion by NK cells. When poly(I:C) i.p. injection induced NK
cell trafficking into the peritoneum, bLF oral administration
increased NK cell accumulation. Oral administration of bLF
immediately induced the elevation of portal interleukin-18
(IL-18) levels. In IL-18 knockout mice, bLF could not en-
hance the number of NK cells. However, NK cell cytotoxic
activity and poly(I:C)-induced trafficking activity were en-
hanced by oral bLF administration even in IL-18 knockout
mice. Furthermore, oral bLF administration augmented the
expression of type-I interferons (interferon-a and -b) in
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Peyer’s patch and the mesenteric lymph nodes. Oral admin-
istration of 2-chloroadenosine reduced the number of
Peyer’s patch cells, and remarkably prevented the ability of
oral bLF administration for NK cell accumulation in the
peritoneum after poly(I:C) i.p. injection. Collectively, these
results indicated that orally administered bLF stimulated in-
testine-associated immune functions, including the produc-
tion of IL-18 and type-I interferons, and then raised the NK
cell activity.
Comparison of antimicrobial activity between
lactoferricin B 15 derivative and antibiotics
Zigang Tian, Jianhua Wang, Da Teng, Yalin Yang, Fan Zhang, Xingjun Feng,
Lingyun Wei, Ying Fan, and Jin Luo
Gene Engineering Laboratory, Feed Research Institute, Chinese Academy of Agricultural
Sciences, Beijing 100081, China
The cationic antimicrobial peptide lactoferricin B15
(LfcinB15, FKCWRWQWRWKKLGA), was synthesized by
chemical method. In vitro susceptibilities of LfcinB15 and
four antibiotics for clinical useage (benzylpenicillin, chlorte-
tracycline hydrochloride, streptomycin, doxycycline) were
evaluated against several gram-positive and gram-negative
bacteria and against Pichia pastoris GS115 using a modified
microtitre broth dilution method by the Hancock laboratory.
The tested peptide showed different antimicrobial activity
against 6 species of microorganisms. Obviously, the gram-
positive bacteria are much more sensitive to LfcinB15 than
the gram-negative bacteria are. LfcinB15 has more broad-
spectrum, but lower, antimicrobial activity against bacteria
when compared with 4 kinds of traditional antibiotics. Its
antimicrobial mechanism is unique and the characteristic of
bacterial resistance forming has not been found. It can be
expected that the methods and results of this study are help-
ful for the future evaluation and screening of other synthe-
sized and recombinant LfcinB derivatives.
This project is funded by the Chinese National Hi-Tech
Research and Development Programs Nos. 2004AA246040
and 2003AA241160–01.
Batch extraction of lactoferrin from raw whole
milk
N.A. Thomson, A. Chand, and C.J. Fee
Dexcel Limited, Hamilton, New Zealand; Department of Materials and Process
Engineering, The University of Waikato, Hamilton, New Zealand
On-farm fractionation of milk proteins is a patented proc-
ess that allows extraction of highly valuable components out
of raw whole milk immediately after harvest. The produc-
tion of high-value dairy proteins such as lactoferrin (LF)
and lactoperoxidase (LP) normally involves extensive pre-
treatments of milk; for example, cooling for storage and
transportation, centrifugation to remove fat, and precipita-
tion or filtration to remove caseins. Preprocessing may cause
loss in protein activity and yield or both. Similar processing
is also applied for processing milk proteins such as recombi-
nant lactoferrin (rLF) from transgenic animals.
LF and LP were used as model proteins to demonstrate
the concept of direct capture of high-value components
from milk. A cation exchanger, an SP Sepharose Fast
FlowTM (GE Healthcare, Uppsala, Sweden), was used in a
single-stage stirred tank to extract LF. Raw whole milk
from individual cows, representing a range of feed LF con-
centrations, was used for extractions. Experimental data ob-
tained for resin–milk ratios of 0.010 to 0.024 over time were
modelled using a composite non-linear model (CNL) (Rowe,
G.E., et al. 1999. Biotechnol. Bioeng. 65(6)). The effects of
adsorption rates, resin–milk ratios, feed LF concentrations,
and adsorption capacity of resin on extraction were investi-
gated. Maximum percentages of original LF extracted by SP
Sepharose Fast FlowTM were 67%, 80%, 88%, and 90%
for extraction times of 5, 10, 20, and 30 min, respectively.
Results from these batch experiments demonstrated that sin-
gle-stage batch extractions can be used to extract LF. Resin–
milk ratios and adsorption times can be manipulated to
achieve the desired yields of LF.
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Modulatory effects of oral administration of
enteric-coated lactoferrin on neutrophil functions
in Feline Immunodifiency Virus (FIV) infected cats
R. Sato, Y. Kobayashi, S. Kobayashi, J. Sato, Y. Yamada, Y. Naito, and J. Sasaki
Department of Veterinary Internal Medicine, Iwate University, Japan
Feline immunodeficiency virus (FIV) infection shows a
similar clinical time-course to human immunodeficiency vi-
rus (HIV) infection. We previously reported anti-inflamma-
tory effects of bovine lactoferrin (bLF) on intractable
stomatitis in cats infected with FIV, and we also clarified
the regulatory effects of bLF on neutrophil functions in
these cats. On the other hand, enteric-coated LF was made
to avoid pepsin disintegration of the stomach. Recent studies
reveal that enteric-coated LF has biological activites on both
the central nerve system and lipid metabolism. In the present
study, we investigated whether enteric-coated LF shows
modulatory effects on neutrophil functions in the same way
that bLF does in FIV-infected cats.
Healthy and FIV-infected cats were orally administered
one enteric-coated LF tablet (containing 90 mg of bLF; 18–
28 mg/kg body mass) for 7 d and neutrophil functions were
investigated before and 7 d post-administration initiation.
Bovine LF was also administered for 7 d (therapeutic dose;
40 mg/kg body mass) and neutrophil functions were investi-
gated in the same manner.
Activities of neutrophil phagocytosis were significantly
increased after administration of enteric-coated LF and bLF
in FIV-infected cats. Luminol-induced chemiluminescence
of neutrophils stimulated by opsonized zymozan did not
show significant changes in either cat group. Neutrophil ad-
herence activity was decreased after administration of en-
teric-coated LF and bLF. Enteric-coated LF showed
modulating effects on neutrophil functions in FIV-infected
similar to the effects of bLF. Therefore, it seemed that en-
teric-coated tablets enable the reduction of the dose of bLF.
Bovine LF induces anti-inflammatory effects in FIV-infected
cats with intractable stomatitis through its neutrophil-regula-
tion activities. Therefore, there is the possibility that a
smaller than therapeutic dose of enteric-coated LF may
show anti-inflammatory effects in FIV-infected cats.
Novel antimicrobial lfampin from lactoferrin
released by a one-enzyme strategy
J.G.M. Bolscher, M.I.A. Van der Kraan, K. Nazmi, H. Kalay, C. Grun, W. Van‘t Hof,
E.C.I. Veerman, and A.V. Nieuw Amerongen
Department of Oral Biochemistry, ACTA, Amsterdam, and Department of Molecular Cell
Biology and Immunology, VU Medisch Centrum, Amsterdam, Netherlands
Antimicrobial peptides have been found throughout na-
ture, yet antimicrobial domains may still lie hidden within a
wide variety of multifunctional proteins. The objective of
this study was to develop a rational strategy to select do-
mains of interest based on the presumed common features
of antimicrobial peptides, and to functionally release these
from accessible and safe proteins. To demonstrate the proof
of principle, bovine lactoferrin (bLF) was screened for suit-
able stretches, including a cationic amphipathic a-helix.
Subsequently, proteolytic enzymes were selected that can
theoretically release the potential antimicrobial sequences.
These sequences were chemically synthesized or isolated
from the native molecule and subsequently tested for their
killing activity. Peptides corresponding to the identified anti-
microbial domain, designated LFampins, indeed possessed
broad-spectrum antimicrobial activity. In silico proteolysis
simulations of bLF with selected endoproteinases predicted
the liberation of peptides containing the required LFampin
sequence. Three predicted peptides were synthesized and
tested for their biological activity, elucidating that a single
enzyme (endoproteinase AspN) was sufficient to obtain an
antimicrobial peptide. The final proof of principle demon-
strated that a 32-mer fragment, LFampin 265–296, isolated
from the AspN-digestion of bLF, possessed antimicrobial
activity as strong as that of the synthetic LFampin. More-
over, AspN digestion of bLF increased its antimicrobial ac-
tivity by release of antimicrobial stretches.
Financially supported by the Dutch Technology Founda-
tion, STW, grant No. VTH5180; the Dutch Dairy Associa-
tion; and DMV International.
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Efficacy of oral bovine lactoferrin on the
interferon a plus ribavirin therapy for chronic
hepatitis C patients with genotype 1b and a high
viral load
M. Kaito, K. Yamauchi, M. Iwasa, Y. Kobayashi, N. Fujita, H. Tanaka, S. Horike,
M. Konishi, S. Watanabe, S. Teraguchi, and Y. Adachi
Department of Gastroenterology and Hepatology, Division of Clinical Medicine and
Biomedical Sciences, Institute of Medical Science, Mie University, 1.2-174 Edobashi, Tsu,
Mie 514-8507, Japan
Many types of interferon (IFN) therapy for chronic hepa-
titis C (CHC) have been developed, but the efficacy of these
therapies has been not high enough. Therefore, various at-
tempts to enhance the efficacy of IFN have been tried.
In the present study, we examined the efficacy of LF at a high
dose (3.6 g/d) for 8 weeks before IFN–ribavirin (IFN–RBV)
therapy. Eighty-seven CHC patients with genotype 1b and a
high viral load (the mean load was >2500  104 copies/mL)
were randomized to an LF group and a control group. Patients
in both groups received the IFN–RBV therapy for 24 weeks.
From 8 weeks before the start until the end of INF–RBV ther-
apy, patients in the LF group received bovine LF (Morinaga
Milk Industry) orally at a dose of 3.6 g/d.
There was no significant difference in the sustained viro-
logical response (SVR) between the 2 groups. Although
INF–RBV therapy achieved a similar SVR in the 2 groups,
the viral load was reduced significantly in the LF group. The
SVR of the LF subgroup, with a decrease in viral load by at
least 50% owing to LF administration, was significantly
higher than in the control group.
It is not sufficient to cure CHC patients even with the
most recent therapy (PEG-IFN plus RBV therapy), the SVR
of which is only 47.6%. Addition of LF treatment to IFN
therapy is expected to increase the chance of recovery in pa-
tients who respond to LF.
Cervical inflammatory cytokines and other
markers in cervical mucus of pregnant women
with bacterial vaginosis
K. Mitsukawa, K. Otsuki, M. Sawada, K. Yakuwa, A. Hasegawa, Y. Sasaki, H. Chiba,
M. Nagatsuka, and T. Okai
Department of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo,
Japan
There is little debate that chorioamnionitis (CAM) results
in preterm delivery from an ascending infection caused by
bacterial vaginosis and cervicitis, both thought to occur be-
fore CAM. Many other studies have already demonstrated
that lower genital-tract inflammation and infection are risk
factors for preterm delivery. In this study, we determined
concentrations of interleukin-6 (IL-6), interleukin-8 (IL-8),
lactoferrin (LF), and a-defencine (a-DF) in cervical mucus
of pregnant women and analyzed their relation to bacterial
vaginosis.
After obtaining both approval from the ethics committee
and patient consent, we obtained cervical mucus samples
from 87 pregnant women: 67 with uneventful pregnancies
(group A), 9 with intermediate type (group B), and 13 who
had bacterial vaginosis (group C). The samples were ana-
lyzed for LF, DF, IL-6, IL-8, and elastase (EL).
The LF, IL-6, and EL concentrations in group C were sig-
nificantly higher (p < 0.05) than in group A. The a-DF and
IL-8 concentrations in group C were higher than in group A.
There were no significant changes in concentrations of LF,
a-DF, IL-6, IL-8, and EL in group B compared with
group A.
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The higher LF, IL-6, and EL concentrations in cases of
bacterial vaginosis may indicate faster defense in the cervix.
Consequently, measurement of these inflammatory marker
concentrations may lead to early detection of lower genital-
tract inflammation and infection.
Lactoferrin inhibits human BK polyomavirus
adsorption to Vero cells
A.M. Degener, G. Longhi V, M. Mischitelli, C. Longhi, M.P. Conte, P. Valenti,
L. Seganti, M. Marchetti, and F. Superti
Departments of Experimental Medicine and Pathology, and Public Health, La Sapienza
University, Rome, Italy; Department of Experimental Medicine, II University of Naples,
Naples, Italy; Department of Technology and Health, National Institute of Health, Rome,
Italy
BK virus (BKV) is a human naked polyomavirus respon-
sible for productive, persistent, and latent infections of the
urinary tract. The presence of its DNA has been revealed in
various tumors. The severity of BKV infection in immuno-
compromised hosts has improved the search for selective
antiviral agents, but hitherto only few effective compounds
have been identified. Lactoferrin (Lf), a member of the
transferrin family, is a biglobular iron-binding glycoprotein
found in milk, exocrine secretions of mammals, and in sec-
ondary granules of polymorphonuclear neutrophiles. Lf was
established as playing an important role in the defence
against various pathogenic microorganisms. Previously, we
demonstrated that Lf is a potent inhibitor of infection by
some enveloped and naked viruses in different cell systems.
In this research, we investigated the effect of this glycopro-
tein on BKV infection. The experiments were carried out
synchronizing infection by a temperature shift and viral rep-
lication in Vero cells and was monitored measuring BKV
DNA synthesis by semiquantitative PCR assay of the TAG
region. The results showed that inhibition of BKV replica-
tion already occurred when Lf was added during viral ad-
sorption. Moreover, pre-incubation of Lf with BKV before
infection inhibited viral replication by 98%, suggesting a
specific binding of Lf to the virions. Finally, the direct inter-
action of Lf to BKV particles was demonstrated by hemag-
glutination inhibition assays and visualized by transmission
electron microscopy. These results demonstrated that, simi-
larly to data obtained with other viruses, Lf inhibits the
early steps of infection through a direct interaction with vi-
ral structures. Further studies will be carried out to better
clarify the effects of Lf on human polyomavirus replication.
Determination of lactoferrin in bovine milk,
colostrum and infant formulas by optical biosenso
analysis
H.E. Indyk and E.L. Filonzi
Fonterra, PO Box 7, Waitoa, Waikato, New Zealand
An automated, rapid, sensitive, and label-free biosensor-
based immunoassay for lactoferrin in bovine milk using sur-
face plasmon resonance (SPR) optical detection is described.
Lactoferrin content was estimated from its specific interac-
tion with an anti-bovine lactoferrin antibody immobilized
on the sensor surface in a direct binding assay format. Sam-
ples were prepared for analysis by direct dilution into buffer.
Analysis conditions, including ligand immobilization, flow-
rate, contact time, and regeneration, were defined and non-
specific binding considerations evaluated. Performance pa-
rameters included a working range of 0–1000 ng/mL, a
method-detection limit of 19.9 g/mL in fluid milk, overall
instrument response RSDR of 3.50%, a mean inter-assay
RSDR of 10.8% for milk powder, and surface stability over
approximately 500 samples. The technique was applied to
the measurement of lactoferrin content of consumer milks,
colostrum, and infant formulas. The influence on lactoferrin
content of temporal change during early bovine lactation,
and the effects of heat on denaturation, were evaluated.
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Design and construction of tandem multimers
lactoferricin B15 derivative for high-level
expression in Escherichia coli
Zigang Tian, Jianhua Wang, Da Teng, Yalin Yang, Fan Zhang, Xingjun Feng,
Lingyun Wei, Ying Fan, and Jin Luo
Gene Engineering Laboratory, Feed Research Institute, Chinese Academy of Agricultural
Sciences, Beijing 100081, China
A combination of multimerization and a Trx fusion pro-
tein were used to mask the toxicity of a lactoferricin B15
(LfcinB15) derivative in Escherichia coli BL21 (DE3). The
CNBr recognition site was introduced to the N- and C-termi-
nals of the peptide to facilitate the final release and separa-
tion of the recombinant peptide. The synthetic genes were
ligated tandemly by cohesive ends to form multimerization
genes, then ligated with linearized and dephosphorylated
pET32a(+) by BamHI and Hind adapters. Transformation
and screening was then carried out via E. coli DH5a and
BL21(DE3) competent cells, respectively. The recombinant
plasmids were confirmed by PCR analysis and DNA se-
quencing. Finally, 8 recombinant plasmids, pET32-
LfcinB15–1, –2, –3, –4, –5, –6, –7, and –9, were obtained
in which difference amongst recombinants, even if it oc-
curred in only one copy, was clearly visible. DNA sequenc-
ing results showed that all 8 recombinants were in frame
and their sequences were also correct. This is an important
basis for further research on expression, purification, and
characterization of the recombinant peptide.
This project is funded by the Chinese National Hi-Tech
Research and Development Programs Nos. 2004AA246040
and 2003AA241160–01.
Visualization of lactoferrin binding to
bifidobacteria
Rahman Md. Morshedur, Woan-Sub Kim, Toshiaki Ito, Haruto Kumura, and Kei-
ichi Shimazaki
Laboratory of Dairy Science, Hokkaido University, Japan
The antimicrobial activity of lactoferrin has been well es-
tablished for many years. However, lactoferrin does not in-
hibit the growth of certain lactic bacteria, including
bifidobacteria; rather, it stimulates their growth. Several
studies have reported that human or bovine lactoferrin pro-
motes the growth of bifidobacteria in vitro and in vivo.
Currently, the most important issue is how lactoferrin pro-
motes the growth of bifidobacteria. It is reported that many
microorganisms have lactoferrin-binding proteins or recep-
tors. Therefore, one possible mechanism of stimulating the
growth of bifidobacteria is the presence of lactoferrin-bind-
ing protein in bifidobacteria. Our previous studies revealed
the presence of such a binding protein.
In this study, we visualized the binding of bovine lacto-
ferrin to bifidobacterial cells (B. infantis 21143 I 63–7)
under native conditions. Binding of lactoferrin was inspected
by confocal laser scanning microscopy (CLSM) using bioti-
nylated lactoferrin and FITC-conjugated streptavidin and
also by transmission electron microscopy (TEM) using bio-
tinylated lactoferrin and gold-conjugated streptavidin. Lacto-
ferrin-binding protein in the membrane fraction of
bifidobacterial cells was also investigated by far-Western
blotting using biotinylated lactoferrin and horseradish perox-
idase conjugated streptavidin.
The results show the binding pattern of bovine lactoferrin
to bifidobacterial cells under native conditions and also sup-
ports the previous findings by far-Western blotting showing
the presence of lactoferrin-binding protein in bifidobacteria.
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Antimicrobial activity of lactoferrin against
Enterobacter Sakazakii
H. Wakabayashi, T. Andoh, K. Yamauchi, and M. Takase
Nutritional Science Laboratory, Morinaga Milk Industry Co. Ltd, Japan
Enterobacter sakazakii is an opportunistic pathogen impli-
cated in outbreaks of meningitis or enteritis with high mor-
tality, especially in neonates and infants. The effect of host
defence factors on the bacterium has rarely been reported.
We investigated whether lactoferrin (LF) or its derivatives
is effective for inhibition of the bacterium. Minimum inhib-
itory concentration (MIC) testing was performed against Es-
cherichia coli O111 and E. sakazakii ATCC51329 by 17 h
incubation in 1% peptone broth with approximately 105
cells/mL of inoculum. MIC (mg/mL) against these strains
was 2000 and 250 for bovine LF, >8000 and 250 for human
LF, 250 and 500 for bovine LF-pepsin hydrolysate, and 16
and 31 for lactoferricin (LFcin) B, respectively. Bovine LF
at 4000 mg/mL exhibited a killing effect on E. sakazakii.
These results suggest that E. sakazakii may be more sensi-
tive to the bacteriostatic effect of LF through iron depriva-
tion than to the bactericidal effect mediated by the LFcin
domain or peptide. Now, we are extending the investigation
by increasing a number of test strains.
Lactoferrin inhibits lipid peroxidation in chronic
hepatitis C patients
Motoh Iwasa, Masahiko Kaito, Koji Yamauchi, Ryosuke Sugimoto, Mika Yamamoto,
Naoki Nakagawa, Masayoshi Konishi, Shozo Watanabe, Susumu Teraguchi, and
Yukihiko Adachi
Department of Gastroenterology and Hepatology, Division of Clinical Medicine and
Biomedical Sciences, Institute of Medical Science, Mie University, 1.2-174 Edobashi, Tsu,
Mie 514-8507, Japan
Oxidative stress plays an important role in the patholo-
genesis of chronic hepatitis C (CHC). Trials with antioxi-
dants have been carried out to influence the progress of the
disease. Bovine lactoferrin (bLF), a milk protein of the iron-
transporter family, is commercially available as a health
food in Japan. Previous studies have shown that LF inhibits
lipid peroxidation in vitro. The present study evaluated the
effects of bLF on plasma 8-isoprostane, serum aminotrans-
ferase levels, viral load, and iron metabolism markers in pa-
tients with CHC.
Fifty-eight outpatients with CHC were enrolled in the
present study. The inclusion criteria were as follows: high
serum levels of HCV RNA (more than 100 kIU/mL as
measured by amplicor monitor assay and serum HCV geno-
type 1b), and absence of other causes of CH. They were ran-
domly assigned into 2 groups. Thirty-seven patients (23 men
and 14 women; mean age 56 years) received oral bLF for
2 months at the daily dose of 3.6 g (Nutritional Science
Laboratory, Morinaga Milk Industry, Zama, Japan).
Twenty-one patients (13 men and 8 women; mean age
58 years) that were not treated with bLF served as controls.
During the observation periods, other medications were not
used.
At entry, the plasma 8-isoprostane was significantly ele-
vated in CHC patients as compared with controls. There
was no significant difference between the 2 groups regard-
ing age, sex, serum aminotransferase, HCV RNA levels, or
iron metabolism markers. Plasma 8-isoprostane levels signif-
icantly (p < 0.05) decreased from 8.9 ± 3.9 to 7.6 ± 4.6 pg/
mL after bLF treatment. In the bLF group, AST and ALT
levels significantly decreased from 62 ± 52 to 46 ± 34 IU/L
and 84 ± 78 to 61 ± 54 IU/L, respectively (p < 0.05). The
serum levels of viral load, iron, ferritin, and transferring sat-
uration remained unchanged throughout the study in both
groups.
Increased oxidative stress, as measured by plasma level of
8-isoprostane, was observed in patients with CHC. Lipid
peroxidation induced liver damage was reduced by bLF in
patients with viral hepatitis C. The results of this study sug-
gest that bLF can be used as a supportive therapy to combat
liver damage caused by lipid peroxidation.
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Effects of human lactoferrin on the chemotactic
response of THP-1 cells
K. Nakashima, Y. Yumoto, and Y. Furuichi
Hokkaido University of Health Sciences, Department of of Periodontology, School of
Dentistry, 1757 Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido 061-0293, Japan
Gingival crevicular fluid in periodontal pockets contains
LPS derived from periodontopathic bacteria and human lac-
toferrin (hLf) released by neutrophils. HLf inhibits LPS in-
teraction with CD14, decreasing TNF-a release from LPS-
stimulated monocytic cells. Bacterial components, e.g.,
fMLP and LPS, also function as chemoattractants. However,
whether hLf affects the chemotactic response of monocytic
cells is unclear. This study examined the effects of hLf on
chemotactic response to various chemoattractants. Human
monocytic cells, THP-1 cells, were cultured in RPMI 1640
medium in the presence of 1a,25-dihydroxyvitamin D3 for
24 h. THP-1 cells were then washed and transferred to the
upper chamber set in a 24-well culture plate; the lower
chamber contained either fMLP, LPS from Escherichia coli,
IL-8, MCP-1, or hLf (Boyden chamber method). Following
a 1 h incubation, the membrane on the floor of the upper
chamber was removed and stained with Diff-Quik1 to meas-
ure absorbance at 595 nm. Quantification of the chemotactic
response of cells was evaluated via calculation of the che-
motactic index (CI) (absorbance in the presence of chemoat-
tractant vs. absorbance in the absence of chemoattractant).
CIs for fMLP, LPS, IL-8, and MCP-1 were 2.00, 2.75, 1.46,
and 1.59, respectively. CIs changed to 1.77, 1.90, 3.27, and
3.32, respectively, after additions of hLf. CI for hLf was
1.50; furthermore, it did not change significantly after intro-
duction of polymyxin B, which indicated that the chemotac-
tic response is not due to contamination of LPS. IL-8 and
MCP-1 levels were significantly higher in the upper cham-
ber in comparison with the lower chamber upon addition to
the lower chamber of hLf as a chemoattractant. These find-
ings suggest that hLf, which acts as a chemoattractant while
suppressing enhanced chemotactic response to LPS, plays an
important role in regulation of monocytic cell chemotaxis.
Promotional effect of bovine lactoferrin on the
growth of bifidobacteria and their mechanism
S. Tomita, T. Uotani, N. Sueki, K. Fujimoto, J. Matsuyama, and Y. Benno
Faculty of Agriculture, Tamagawa University; Japan Collection of Microorganisms, RIKEN
BioResource Center
Lactoferrin (LF) has a bacteriostatic effect against putre-
factive bacteria such as clostridia, but does not inhibit the
growth of beneficial bacteria such as bifidobacteria. Bifido-
bacteria are probiotics that have been implicated in a num-
ber of beneficial effects such as prevention of
gastrointestinal infections in humans and animals. The aim
of this study is to clarify the mechanism for the growth pro-
motional effect of LF on bifidobacteria.
Bifidobacteria strains in GAM liquid medium with LF
were incubated anaerobically at 37 8C for 8 h. Viable counts
were determined by plating serial dilutions onto GAM agar
plates. The growth of Bifidobacterium breve JCM1192 with
LF increased about 20% compared with that without LF, but
B. breve JCM7017 was barely affected. The binding abilites
of LF to the cells of B. breve JCM1192 and JCM7017 were
observed by an enzyme-linked ligand-binding assay using a
horseradish peroxidase – LF (HRPO–LF) conjugate. The
binding ability of LF to the cells of B. breve JCM1192 was
significantly higher than that to cells of JCM7017. The ex-
tents of the binding of apo-LF to the cells of each strain
were the same as those of Fe-LF. The LF binding site on
the bifidobacterial cell was investigated. Detection of an
LF-binding protein (BP) in surface components of cells ex-
tracted with guanidine hydrochloride was done by 2-dimen-
sional PAGE andWestern blotting using HRPO–LF
conjugate. Two spots corresponding to LF-BP were detected
in B. breve JCM1192, and had relative molecular masses of
about 36 kDa and isoelectric points of about 6.3 and 6.4, re-
spectively. However, BP was not detected in B. breve
JCM7017. BP binding to other milk proteins was not con-
firmed in this study.
These results suggest that the growth promotional effect
of LF on bifidobacteria may be mainly responsible for LF
binding to LF-BP on the cell surface.
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Lactoferrin in bovine milk is not affected by strain
of cow or level of feed
S.-A. Turner and N.A. Thomson
Dexcel Ltd, Cnr. Ruakura and Morrinsville Roads, Private Bag 3221, Hamilton,
New Zealand
Methods of increasing the concentration of lactoferrin
(Lf) in bovine milk could be valuable to processors inter-
ested in extracting Lf from milk. Previous work has shown
that time of year, stage of lactation, and strain of cow affect
milk Lf concentration. To investigate whether Lf in milk
could be elevated by the selection of cows of particular
strains, and (or) feeding a particular level of feed, a study
was undertaken utilizing the milk samples collected from 6
herds of cows being farmed as part of a larger study to eval-
uate the performance of 3 strains of Holstein–Friesian cows
in a range of farming systems. The trial included two high-
breeding-worth ($BW) strains of either North American
(OS90) or New Zealand (NZ90) genetics, and one low
$BW strain of NZ genetics (NZ70) in 6 farm systems de-
signed to provide feed allowances ranging from 5.0 to
6.5 tDM/cow.y–1. Cows were grazed on a pasture, with the
6 and 6.5 tDM herds being offered maize silage in the pad-
dock during pasture deficit periods. Herds examined were
NZ70s at 5.5 tDM; NZ90s at 5, 5.5, 6, and 6.5 tDM; and
OS90s at 5.5 tDM and contained 15 (NZ70s) or 20 (NZ90
and OS90) cows/herd. Milk samples were collected individ-
ually from all cows in September (47 d in milk; DIM), No-
vember (96 DIM), and February (197 DIM) in both the
2002–2003 and 2003–2004 seasons. Data are the average of
both seasons. No effect of strain on Lf concentrations was
apparent for cows in the 5.5 tDM herds in September (65,
99, 65 mg/L; NZ70, NZ90, OS90, respectively), November
(73, 99, 112 mg/L), or February (90, 109, 99 mg/L). No ef-
fect of feed level on Lf concentrations was apparent for the
NZ90 cows in September (93, 99, 120, 99 mg/L; 5, 5.5, 6,
6.5 tDM, respectively), November (111, 93, 136, 124 mg/
L), or February (136, 109, 136, 136 mg/L). The lack of
strain effect on Lf concentrations is contradictory to previ-
ously published results and may suggest that the OS90
cows were not receiving adequate nutrition at the compara-
tively low feeding level of 5.5 tDM/cow.y–1. These results
also suggest that feeding level cannot be used to manipulate
Lf concentrations in the milk of NZ90 pasture-fed Friesian
cows.
Bovine lactoferrin reduces concanavalin A-
induced interferon-g expression of peripheral
blood mononuclear cells in FIV-negative and FIV-
positive cats
S. Kobayashi, R. Sato, O. Inanami, T. Yamamori, M. Kuwabara, Y. Naito, and
M. Takase
Iwate University, Department of Veterinary Internal Medicine, Faculty of Agriculture, 3-18-
8, Ueda, Morioka 020-8550, Japan
We previously reported anti-inflammatory effects of bo-
vine LF (bLF) on intractable stomatitis in cats infected with
feline immunodeficiency virus (FIV), a model of HIV infec-
tion. Futhermore, it revealed that bLF modulates neutrophil
functions including phagocytosis and adherence. In this
study, to clarify the anti-inflammatory effects of bLF, we in-
vestigated the effect of bLF on feline lymphocyte functions.
In addition, we also examined the relation between the ef-
fect of bLF and the intracellular-activated protein kinases.
Peripheral blood mononuclear cells (PBMCs) were ob-
tained from FIV-negative and FIV-positive cats. The prolif-
eration was measured using the MTT colorimetric method.
Bovine LF was added to the PBMCs 30 min before and
40 min after concanavalin A (ConA) stimulation. After
RNA extraction, interferon-g, interleukin-1b, TNF-a, and in-
terleukin-12 p40 mRNA expression were detected by semi-
quantitative or real-time RT-PCR. The activation of
extracellular signal regulated kinases (ERKs) and protein ty-
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rosine kinases (PTKs) of PBMCs was examined by Western
blotting, which used the phosphorylated antibody in FIV-
negative cats.
LF inhibited the ConA-induced PBMC proliferation in a
dose-dependent manner. RT-PCR showed a ConA-induced
increase of interferon-g mRNA expression, but not of inter-
leukin-1b, TNF-a, or interleukin-12 p40 mRNA in both fe-
line PBMCs. This ConA-induced increase of interferon-g
mRNA expression was significantly inhibited by bLF addi-
tion not only 30 min before but also 40 min after ConA
stimulation. Especially, the inhibitory effect was more
strong in FIV-positive cats with intractable stomatitis. Using
specific kinase inhibitors of ERK (PD098059) and PTK
(genistein), we found that the increase of ConA-induced in-
terferon-g mRNA expression was ERK and PTK dependent.
Western blotting revealed that the activation of PTK and
ERK kinases had almost disappeared by 40 min after ConA
stimulation.
These results suggest that bLF inhibits the ConA-induced
interferon-g mRNA expression by abrogation of intracellular
inflammatory effects of bLF in vivo, which seems to be
mediated in part through lymphocyte functions such as local
cytokine production.
Effect of enteric-coated lactoferrin on
constipation during pregnancy
K. Otsuki, K. Yakuwa, M. Sawada, K. Ichizuka, M. Nagatsuka, T. Kimura, and
T. Okai
Department of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo
142-8666, Japan
Symptoms of constipation, menstrual colic, discharge, and
preterm labor are related to menstruation, aging, lower geni-
tal-tract infections, and pregnancy. We evaluated the allevia-
tion of these symptoms, particularly during pregnancy, by
oral administration of enteric-coated lactoferrin (LF, tablet,
NRL-Pharma Inc.).
This study was approved by the Showa University School
of Medicine ethics committee. Following an explanation of
this study, each of the 7 women (6 at 19 to 32 weeks of
pregnancy at the start of the study and 1 non-pregnant sub-
ject) agreed to participate. All 7 were taking medication for
constipation (typically 1000–2000 mg/d MgO2). Three of the
6 pregnant women were hospitalized for observation owing
to preterm labor and cervical insufficiency, while the re-
maining 3 showed normal course and outcome and were not
taking any additional known anti-inflammatory medications.
Before and after the administration of LF (400 mg/d for at
least 1 month), symptoms of constipation, menstrual colic,
discharge, and preterm labor were observed and recorded.
Cervical mucus and vaginal fluid samples were collected
for the determination of elastase concentration and for bacte-
rial culturing, respectively.
Six of the 7 subjects experienced remarkable reductions in
both the dose and frequency usage of constipation medicine
within a few days of starting LF administration. Further,
symptoms of constipation eased and frequency of bowel
movements increased. Bacterial flora of the vaginal fluid
and inflammatory markers in cervical mucus did not change
significantly.
As previously reported, LF administration has the poten-
tial to reduce many minor discomforts associated with preg-
nancy, particularly common constipation. While the
mechanisms remain unclear, direct and indirect (combina-
tion with bile) effects were suspected to affect the bacterial
flora of the digestive ducts (the small intestine and the rec-
tum) in the mitigation of constipation. Further studies on
clinical use of LF, particularly for pregnant women, are
needed.
Towards a tree-induction approach to
antimicrobial activity analysis of cationic peptides
S. Farnaud, Z. Wang, R. Dybowski, E.W. Odell, and R.W. Evans
King’s College London, Randall Division of Cell and Molecular Biophysics, Guy’s
Campus, New Hunt House 3/6b, London SE1 1UL, UK
Owing to their ever-increasing number and diversity, anti-
microbial cationic peptides can be a valuable tool against
the growing occurrence of resistant microorganisms. Their
modes of action, however, remain unidentified. The antimi-
crobial properties of lactoferrins are partly attributed to the
lactoferricins, the antimicrobial peptides that correspond to
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the N-terminus region of lactoferrin after pepsin cleavage of
human and bovine lactoferrin. To define the relationship be-
tween the structure of these peptides and their antimicrobial
activity, quantitative structure–activity relationship (QSAR)
studies have been performed using a tree-induction approach
and are presented to illustrate their ease of interpretation and
potential applicability in structure–function studies of cati-
onic antimicrobial peptides.
Distribution of human lactoferrin in periodontal
pockets
Y. Yumoto, K. Nakashima, and Y. Furuichi
Department of Periodontology, School of Dentistry, Health Sciences University of
Hokkaido, 1757 Kanazawa, Tubetsu-cho, Ishikari-gun, Hokkaido 061-0293, Japan
Periodontopathic bacteria endotoxin permeates dental root
surfaces exposed to periodontal pockets, eliciting an inflam-
matory response. Human lactoferrin (hLf) inhibits interac-
tion between LPS and CD14; thus, hLf released by
neutrophils may participate in the inflammatory response.
The present study examined the distribution of hLf in perio-
dontal pockets and its roles in the pathogenesis of periodon-
titis. Nineteen teeth not salvageable by periodontal treatment
were extracted with informed consent of the patients. Five
extracted teeth were incubated with anti-hLf antibody and
Alexa 532-conjugated secondary antibody; subsequently,
fluorescence was measured. Powdered samples were pre-
pared from 14 extracted roots. Samples were partitioned
into 3 groups based on location: layers I, II, and III (from
the root surface to the pulp cavity). Samples were then
washed with PBS; hLf and endotoxin levels in the superna-
tant were measured. Additionally, hLf levels in gingival
crevicular fluid (GCF), saliva, and supra- and sub-gingival
dental plaque of healthy volunteers were determined. Fur-
thermore, human monocytic cells, THP-1 cells, were cul-
tured with hLf and LPS from Escherichia coli for 24 h,
after which LDH activity and cytokine levels (TNF-a, IL-8
and MCP-1) in culture supernatants were measured. Areas
displaying fluorescence were consistent with those areas
characterized by calculus. Significantly higher hLf and en-
dotoxin levels were detected in layer I from areas with cal-
culus relative to layer I from areas lacking calculus. GCF
demonstrated higher hLf levels in comparison with saliva.
LDH activity and cytokine levels increased following LPS
stimulation; however, LDH activity and TNF-a levels de-
creased upon introduction of hLf. These findings suggest
that hLf released by neutrophils is bound to LPS in perio-
dontal pockets, which leads to inhibition of TNF-a release
and enhancement of chemokine release from monocytic
cells.
Effect of lactoferrin on murine melanoma B16-F1
cells; possible mode of action
Jeremy H. Brock, Madalina Icriverzi, Mihaela Trif, Flori Chelu, Gabriela Negroiu,
and Anca Roseanu
Department of Immunology, Western Infirmary, Glasgow G11 6NT, Scotland, UK; Institute
of Biochemistry, Splaiul Independentei 296, 060031 Bucharest, Romania
Lactoferrin (Lf) is a key multifunctional iron-binding gly-
coprotein found throughout the body. Many different roles
have been attributed to lactoferrin, including the primary de-
fence against tumorigenesis. Several studies have reported
that Lf supresses the growth of tumour cells in vitro and re-
duces experimental metastasis induced in mice. However the
mechanism of Lf action is still under debate.
We previously reported that Lf is cytotoxic to murine
melanoma B16-F1 cells by inducing a reduction of cell via-
bility and morphological modifications probably determined
by an apoptotic process.
The aim of this study was to investigate the interaction of
Lf with murine melanoma B16-F1 cells and its effect at the
intracellular level.
We found that Lf specifically binds to the cell surface and
is internalized into B16-F1 cells using immunofluorescence
and an ELISA-type method. We also analyzed the effect of
Lf on the expression of tyrosinases, TRP-1 and TRP-2.
These proteins belong to the tyrosinase-related proteins
(TRP) family and are enzymes catalyzing the major steps in
the synthesis of melanins, the pigment produced by melano-
cytes. TRP-1 and TRP-2 are also involved in other cellular
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functions, such as cell viability, growth, and morphology of
melanocytes. It has also been suggested that TRP-2 might
play a role in modulating apoptotic pathways by controlling
the concentration of 5,6-dihydroxyindole, a very toxic inter-
mediate that, in the absence of the enzyme, would accumu-
late in melanocytes. Our experiments performed by SDS–
PAGE and Western blot with specific antibodies revealed
that Lf down regulated the expression of TRP-2. No effect
on tyrosinase and TRP-1 expression in B16-F1 cells was ob-
served.
These data suggest that Lf is cytotoxic to B16-F1 cells by
down-regulating TRP-2 expression and thus affecting its ca-
pacity to modulate apoptotic pathways.
Efficacy and safety of lactoferrin as a new
preventive reagent for bovine mastitis
K. Kai, M. Itagaki, M. Uematsu, Y. Miyazaki, D. Fukumoto, I. Iwaski,H. Tsuchida,
Y. Taguchi, S. Ishiguro, K. Kumagai, T. Yanaka, and M. Mochizuki
Research and Development, Advanced Technology Development Center, Kyoritsu
Seiyaku Corp., Takamihara, Tsukuba, Ibaraki 300-1252, Japan; Yamagata Prefecture
Federation Agricultural Mutual Aid Association, Kitagawara, Nanaura, Yamagata 990-
2171, Japan; Central Veterinary Clinical Center Tokachi Agricultural Mutual Aid
Association, Kisen Motomatsu-cho, Obihiro, Hokkaido 080-2231, Japan; K. Kumagai,
Sakuraga-oka, Aoba-ku, Sendai, Miyagi 981-0961, Japan; Laboratory of Clinical
Microbiology, Advanced Technology Development Center, Kyoritsu Seiyaku Corp.,
Kudan-minami, Chiyoda-ku, Tokyo 102-0073, Japan
Mastitis is the most costly disease of dairy cows through-
out the world. Intramammary infections during non-lactating
periods can cause mastitis after calving, and the reduction of
bacterial counts in the mammary gland is the ideal preven-
tive method. Since lactoferrin has bactericidal effects and
priming effects on innate immunity, we investigated whether
an intramammary infusion of bovine lactoferrin (bLf) could
safely prevent mastitis. A total of 398 healthy mammary
quarters of 104 cows were used for the study. Thirty-eight
mammary quarters showing high bacterial count in milk
were excluded. To evaluate the preventive effect of bLf on
clinical mastitis development, the remaining 360 mammary
quarters were examined until 3 months after calving. A bLf
group was infused once intramammarily with bLf 7–14 d
after cessation of milking and the other group was kept as a
non-treated control. The numbers of quarters in the bLf
group and the control group were 179 and 181, respectively.
During the test period, 4 quarters (2.2%) were recognized as
having clinical mastitis in the bLf group, in contrast with 20
quarters (11.0%) in the control group. In addition, to evalu-
ate the preventive effect of bLf on subclinical mastitis de-
velopment, 398 mammary quarters of 104 cows were used.
The numbers of quarters in the bLf group and the control
group were 200 and 198, respectively. In the bLf group, 2
quarters (1.0%) were recognized as having subclinical mas-
titis 7 d after calving, compared with 15 quarters (8.7%) in
the control group. Incidence of both clinical and subclinical
types of mastitis in the bLf group was significantly lower
than the control group. No adverse reaction occurred after
the infusion of bLf throughout the study. These results sug-
gest that the infusion of bLf during non-lactating periods has
a preventive effect against mastitis development after calv-
ing.
Human lactoferrin in milk of transgenic animals
E.R. Sadchikova, I.L. Goldman, A.N. Krasnov, S.G. Kadulin, S.G. Georgieva,
T.G. Ermolkevich, Ya. G. Gursky, N.V. Gnuchev, and G.P. Georgiev
Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia
Human lactoferrin is a type of protein, which may have
multiple applications. Therefore, it is critical that it be pro-
duced in large quantities. The ultimate goal is to create a
technology for its mass production. The future will tell
which of the currently developed technologies will provide
the necessary production volume of human lactoferrin and
which will prove to be the most cost efficient.
The Institute of Gene Biology of the Russian Academy of
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Sciences is currently working on a program of human lacto-
ferrin production from the milk of transgenic goats. The aim
is to ensure high concentration of recombinant lactoferrin in
the milk of transgenic animals, which will be identical to
that found in natural animals. To achieve this goal, gene
constructions of human lactoferrin with cDNA were created
under the control of various milk gene promoters and other
regulatory elements. Testing of gene constructions required
over 100 primary transgenic mice and lines of transgenic
mice. Those mice were used to research the level of concen-
tration of human lactoferrin in the milk, transgenic inheri-
tance over generations, as well as some other parameters of
this human protein.
As a result, the gene construction has been chosen which
met all the requirements. This gene construction consists of
a genome copy of human lactoferrin controlled by the goat
casein gene promoter, which provided for the economically
viable level of lactoferrin production in the milk of trans-
genic mice. At the same time, owing to the positioning ef-
fect, the use of this construction caused wide variation of
lactoferrin concentration in the milk of primary transgenic
animals: from 1.5 g/L to 40 g/L. Two generations of trans-
genic mice with a high level of lactoferrin production
showed concentrations over 20 g/L. Lactoferrin concentra-
tion in the milk of transgenic mice during lactation period
varied greatly. Most animals had the highest level of lacto-
ferrin concentration in the middle of their lactation period.
Initial research of recombinant lactoferrin produced in the
milk of transgenic animals confirmed its quality identity to
the human lactoferrin. Natural polymorphism of the lactofer-
rin protein provoked a secondary question concerning the
functional identity of its isoforms. This year, there is task to
initiate research that would result in creation of lactoferrin
transgenic goats.
Effect of dietary bovine lactoferrin on tolerance to
air exposure stress and response in branchial
heat-shock protein under low-salinity conditions
in grouper Epinephelus coioides
Yokoyama Saichiro, Koshio Shunsuke, Teshima Shin-ichi, Ishikawa Manabu,
Reyes-Catacutan Mae, Takakura Natsuko, and Oshida Kyoichi
Laboratory of Aquatic Animal Nutrition, Faculty of Fisheries, Kagoshima University, 4-50-
20 Shimoarata, Kagoshima 890-0056, Japan
Augmentation of mass mortality caused by disease and
stress has been considered as a serious problem in aquacul-
ture worldwide. Therefore, addition of tolerance against
stress for fish is an important task in enabling sustainable
aquaculture. Recently, we clarified that dietary bovine lacto-
ferrin (bLF) enhances tolerance to high-temperature stress in
Japanese flounder, Paralichthys olivaceus; however, there
are no reports on the effect in other important species. In
present study, dietary bLF was administrated to juvenile
grouper (initial mass = 3.0 g) to investigate its effects on
growth response, mucus presence, tolerance to air exposure,
and response in branchial heat-shock protein under low-sal-
inity conditions. Test diets containing 4 different concentra-
tions of bLF (0, 400, 800, and 1200 mg bLF/kg diet) were
fed to specimens for 30 d. After feeding trial, amounts of
secreted mucus on the body surface were measured while
fish were exposed to the air for 60 min to obtain the recov-
ery from respiratory distress condition. Furthermore, fish
were exposed to low-salinity (3.5 ppt) seawater for 0 (no-
stress) and 6 h. After low-salinity seawater exposure, the
levels of heat-shock protein 70 family proteins (HSP70s) in
the branchial lamella were measured by enzyme-linked im-
munosorbent assay. Dietary bLF did not affect growth rate
of this species. Mucus secretion significantly increased in
all bLF-supplemented groups compared with that in the
0 mg bLF group. Recovery rate from the air-exposure stress
test increased with increasing dietary bLF level. Under the
low-salinity exposure, significantly higher levels of HSP70s
were detected in 800 and 1200 mg bLF-supplemented
groups than those in the bLF 0 mg group after both 0 and
6 h exposure. These results suggest that dietary bLF enhan-
ces tolerance to physiological stress, and is an effective
means for evaluating the quality of juvenile grouper.
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Therapeutic effects of bovine lactoferrin on
staphylococcal mastitis during non-lactating
period
K. Kai, Y. Komine, K. Komine, M. Ohta, and K. Kumagai
Research and Development, Advanced Technology Development Center, Kyoritsu
Seiyaku Corporation, Takamihara, Tsukuba, Ibaraki 300-1252, Japan; Intelligent Cosmos
Research Institute, Minamiyoshinari, Aoba-ku, Sendai, Miyagi 989-3204, Japan; M. Ohta,
Choumeigaoka, Izumi-ku, Sendai, Miyagi 981-3212, Japan; K. Kumagai, Sakuraga-oka,
Aoba-ku, Sendai, Miyagi 981-0961, Japan
During the non-lactating period, a few months before
calving, there are increases in the concentration of bovine
lactoferrin (bLf), complement components, and phagocytes
in mammary gland secretions. These may play an important
role in host defense against bacteria. We investigated
whether an intramammary infusion of bLf could effect the
cure rate of mastitis and mammary gland immunity. To
evaluate the clinical effects of bLf on staphylococcal masti-
tis in Holstein cows during the early non-lactating period, 41
mammary quarters were selected randomly from 36 cows on
3 dairy farms. Twelve quarters were infused intramammarily
with bovine lactoferrin. Twenty-nine quarters were infused
with an antibiotic as a control. In the bLf group, 91.7% of
mastitic quarters were cured 7 d after calving, compared
with 48.3% in the control group. Furthermore, the changes
in mammary secretion induced by the infusion of bLf were
investigated. Mean numbers of staphylococci in mammary
gland secretions were significantly decreased in 5 bLf-in-
fused quarters and in 5 antibiotic-infused control quarters.
Unlike in the control quarters, the mean total cell concentra-
tion in the mammary gland secretions increased in bLf-in-
fused quarters. Similar results were obtained in 6 healthy
quarters that were infused with bLf. In these quarters, the
cell population contained mainly phagocytes such as poly-
morphonuclear leukocytes and cells positive for CD11b,
which is known as a complement receptor. The mean con-
centration of C3 in mammary gland secretions was signifi-
cantly increased in 5 mastitic quarters infused with bLf, but
showed no significant change in 5 mastitic control quarters.
These results suggest that bLf treatment for staphylococcal
mastitis in the early non-lactating period might increase the
rate of cure through the induction of innate immunity in the
host.
NMR structural studies of bovine and human
lactoferrampin, novel antimicrobial peptides from
lactoferrin
E.F. Haney, F. Lau, and H.J. Vogel
Department of Biological Sciences, University of Calgary, 2500 University Dr. NW,
Calgary, AB T2N 4N1, Canada
Lactoferrin has been identified as a protein with numerous
functions, one of which is the ability to inhibit bacterial
growth. A pepsin digestion fragment, known as lactoferricin,
has already been implicated in the antimicrobial activity of
lactoferrin. It is found in the highly cationic N-terminal seg-
ment of lactoferrin that distinguishes this protein from other
transferrins. Recently, a novel antimicrobial peptide, lacto-
ferrampin, was identified in the sequence of bovine lactofer-
rin. This fragment is a cationic stretch of 17 amino acids
that lies adjacent to lactoferricin on the surface of the N-ter-
minal lobe of the lactoferrin protein. The bovine lactofer-
rampin peptide (WKLLSKAQEKFGKNKSR) corresponds
to residues 268–284 of bovine lactoferrin. The related hu-
man peptide (WNLLRQAQEKFGKDKSP) corresponds to
residues 269–285 of human lactoferrin and is 70% homolo-
gous to the bovine form, but is less cationic. These 2 pepti-
des have been synthesized and their solution structures have
been determined in SDS and DPC micelles using 2-dimen-
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sional nuclear magnetic resonance (NMR) techniques. The
human and bovine peptides were relatively unstructured in
water; however, both formed amphipathic helices in SDS
micelles. The amphipathic helix is a known motif in many
other antimicrobial peptides where the positively charged
residues interact with the negatively charged bacterial sur-
face and the hydrophobic residues are capable of interacting
with the hydrophobic tails of the peptide-based antibiotics
that are highly selective and efficient against pathogenic
bacteria.
Long-term follow-up of chronic hepatitis C
patients administered oral lactoferrin
K. Higami, K. Ishii, M.L. Shinohara, T. Ikehara, H. Nagai, M. Watanabe, Y. Sumino,
K. Miki, and K. Yamauchi
Division of Gastroenterology and Hepatology, Toho University School of Medicine, Tokyo;
Nutritional Science Laboratory, Morinaga Milk Industry Ltd, Kanagawa, Japan
We have already reported that oral administration of bo-
vine lactoferrin (bLF) to chronic hepatitis C (CHC) patients
produced a Th1-cytokine dominant environment in the pe-
ripheral blood for up to 3 months. The present study at-
tempted to clarify the effects of long-term administration of
bLF on serum parameters and a developing rate of hepato-
cellular carcinoma (HCC) in CHC patients. Daily, 600 mg
of bLf (Morinaga Milk Industry Ltd.) was orally adminis-
tered to 25 CHC patients (bLf group) and they were fol-
lowed for a median of 56 months (range: 25–72 months).
Serum parameters and a developing rate of HCC were com-
pared with those of a control group, which included sex- and
age-matched CHC patients (a median of 55 months; range:
12–72 months). HCC was histopathologically diagnosed us-
ing tumor biopsy specimens. Serum parameters included
ALT, iron, ferritin, and quantitative HCV-RNA by RT-PCR
(Amplicor v. 2.0; Roche, Basel, Switzerland).
Serum parameters were not significantly changed during
the period, nor were those of the control. HCCs were devel-
oped in 3 patients from the bLF group (2.7% per person per
year) and in 3 patients from the control group (2.9% per
person per year). The developing rate of HCC was not dif-
ferent between 2 groups.
These results suggest that oral bLF may not prevent de-
veloping HCC, although further follow up for those patients
and investigation will be needed.
Effects of lactoferrin on adipogenesis in 3t3-l1
cells and obesity mice
M.S. Nam, M.C. Cho, H.C. Bae, and D.Y. Yoon
Laboratory of Milk Food Biochemistry, Division of Animal Science and Resources,
College of Agriculture and Life Sciences, Chungnam National University, Daejeon 305-
764, Korea; Laboratory of Cell Biology, Korea Research Institute of Bioscience and
Biotechnology, PO Box 115, Daejeon 305-333, Korea
This experiment was carried out to investigate effects of
the multifunctional iron-binding glycoprotein lactoferrin on
adipogenesis and obesity mice. Lactoferrin inhibited lipid
drop formation in differentiated 3T3-L1 adipocytes induced
by insulin, dexamethasone, and isobutylmethylxanthin. RT-
PCR revealed that the lactoferrin receptor was expressed in
3T3-L1 adipocytes. Oral administration into BKS.cg-m+/+
Leprdb obesity mice showed that there was no effect on
body mass increase at high doses of Lf (10 mg/d), whereas
body mass was increased by as much as 30% in control
mice (not administrated) and those administered a low dose
of Lf (5 mg/d). In addition, cholesterol level was reduced in
mice treated with a high dose of Lf (10 mg/d). The results
suggest that Lf plays a potentially important role in reducing
body mass and regulating fat metabolism.
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Lactoferrin in dentistry
Tamaki Yukimichi and Ando Kunio
Showa University School of Dentistry, Department of Oral Biomaterials and Technology,
1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
Although a large amount of research has been carried
out on the structure and function of lactoferrin since its
discovery in 1939, there are a few studies relating to its
dental application. This study deals with its clinical effi-
cacy on such oral diseases as periodontitis, xerostomia, hal-
itosis, stomatitis, angulitis, and glossodynia, since
lactoferrin has immuno-potentiating properties and shows
anti-inflammatory and antinociceptive activities in animal
studies.
Bovine milk lactoferrin used in this study was the product
of Murray Goulburn Co. (Brunswick, Australia). The en-
teric-coated capsules and plain-flat oral patches (8 mm di-
ameter, 1 mm thick) were supplied from NRL Pharma Inc.
(Kawasaki, Japan). The lactoferrin contentof each was
100 mg/capsule and 30 mg/patch, respectively. The patients
enrolled in this study signed their informed consent after an
oral explanation of the experiment. Fresh breath was col-
lected from patients with halitosis early in the morning and
volatile sulfur compounds in breath were determined by gas
chromatography.
The capsules were used for the treatment of severe perio-
dontitis, zerostomia, and halitosis and the patches were used
for treatment of stomatitis, angulitis, and glossodynia. Treat-
ment with these regimens was highly efficacious without
any side effects. Especially, the patch directly applied on in-
jured regions reduced pain within 5 min and seemed to stim-
ulate wound healing. The treatment with the capsules was
also efficacious for severe periodontitis, xerostomia, and
halitosis; the treatment with 3–6 capsules/d rapidly im-
proved dry-mouth caused either by Sjogren syndrome or in-
duced by drugs. Moreover, treatment resulted in significant
reduction of volatile sulfur compounds within a few days.
Consequently, lactoferrin is highly efficacious both when
applied topically on injured oral mucosa and when taken or-
ally as enteric-coated capsules for treating periodontitis, xe-
rostomia, and halitosis.
Killing of pneumococci by apolactoferrin is
dependent on cleavage of apolactoferrin by the
pneumococcal surface serine protease PrtA
Shaper Mirza, William H. Benjamin Jr., and David E. Briles
Departments of Microbiology and Pathology, University of Alabama, Birmingham, AL,
USA
Apolactoferrin (ALF) is known to kill pneumococci and
this killing is largely, but not completely, blocked by pneu-
mococcal surface protein A (PspA). We now report more re-
cent studies showing that the killing of pneumococci by
ALF could be blocked by serine protease inhibitors such as
pneylmethylsulfonylfloride (PMSF) and soyabean trypsin in-
hibitor (SBT). Analysis of the sequenced TIGR4 genome
demonstrated the presence of 3 putative cell-surface-associ-
ated proteases including PrtA. PrtA is a member of the sub-
tilisin-like family of serine proteases (Beth, G., et al. 2001.
FEMS Microbiol Lett. 205(1): 99–104), which is released
from the bacterial surface as an active enzyme. We con-
structed a prtA knockout mutant of strain D39 and found
that it almost completely blocked killing by apolactoferrin.
Further study showed that when apolactoferrin is added to
wild-type and PrtA mutant D39, the ALF in solution with
the wild-type D39 is cleaved, whereas the apolactoferrin in
solution with the PrtA mutant pneumococci was not cleaved.
It is likely that the cleavage by PrtA resulted in the genera-
tion of low-molecular-weight lactoferricins that were the ac-
tual cause of bacterial death. Finally, when we examined the
apolactoferrin bound to PspA, we found that it was not
cleaved by either strain. These findings indicate that binding
to PspA blocks cleavage of ALF by PrtA. Thus, PspA’s
ability to inhibit killing of pneumococci by ALF could
easily be because it prevents cleavage of ALF by PrtA.
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Cleavage of human lactoferrin by a surface-
associated serine protease (PrtA) of
Streptococcus pneumoniae
Shaper Mirza and David E. Briles
Department of Microbiology University of Alabama, Birmingham, AL, USA
Serine protease activity is critical for apolactoferrin (ALF)
to be able to kill pneumococci. Phenylmethyl-sulfonylfloride
(PMSF), a serine protease inhibitor, at a concentration of
7.5 mmol/L is able to block killing by 3.1 mmol/L apolacto-
ferrin. PMSF was not, however, able to block killing by lac-
toferricin, the N-terminal bactericidal fragment of
lactoferrin. These observations suggested that killing of
pneumococci by apolactoferrin may depend on the ability
of a bacterial protease to cleave a lactoferricin peptide from
ALF that actually mediates the killing. Evidence that grow-
ing pneumococci could degrade lactoferrin came from our
observation that incubation of 50 mg/mL apolactoferrin
from human milk with growing pneumococci resulted in a
reduction in molecular mass of the apolactoferrin by about
10 kDa. A targeted mutation resulting in the disruption of
the prtA gene inhibited the degradation of apolactoferrin.
We also observed that capsular type 2 and 19F strains with
prtA mutations became relatively resistant to killing by apo-
lactoferrin (p value > 0.001). Our interpretation of these data
are that prtA acts to cleave lactoferricin from apolactoferrin
and the released lactoferricin is probably the mechanism by
which ALF kills bacteria.
PspA inhibits the antibacterial effect of lactoferrin
on Streptococcus pneumoniae
David E. Briles and Shaper Mirza
Department of Microbiology, University of Alabama, Birmingham, AL, USA
The only surface protein on pneumococci that binds sig-
nificantly to lactoferrin is pneumococcal surface protein A
(PspA). Apolactoferrin binds to the N-terminal half of
PspA. PspA binds to both apo- and holo-lactoferrin. This
binding, however, is not a mechanism for iron acquisition,
since hololactoferrin cannot serve as an iron source for
pneumococci, which acquire their iron from heme. Apolac-
toferrin, but not hololactoferrin, is able to kill pneumococci
during a 1 to 2 h incubation in vitro. PspA very effectively
inhibits the killing of pneumococci by apolactoferrin and by
lactoferricin (an N-terminal fragment of lactoferrin). We
have demonstrated this by comparing the susceptibility to
apolactoferrin and lactoferricin of wild-type pneumococci
with mutants of pneumococci lacking PspA expression. We
have also shown that the soluble N-terminal half of PspA
can inhibit killing of pneumococci by apolactoferrin. Anti-
body to PspA is able to enhance killing of pneumococci by
apolactoferrin. We have shown that antibody to PspA inhib-
its binding of apolactoferrin to PspA, thus explaining how
the antibody may enhance killing by apolactoferrin. Since
lactoferricin is more bactericidal on a molar basis than apo-
lactoferrin, we feel that the mechanism by which apolacto-
ferrin kills pneumococci is by first being cleaved into
lactoferricin. We have shown that for pneumococci to be
killed by apolactoferrin hey must possess the surface serine
protease PrtA. We have also shown that this enzyme can de-
grade apolactoferrin. Thus, it would appear that a bacterial
protease is required for the susceptibility of bacteria to kill-
ing by apolactoferrin. The ability of apolactoferrin to kill
pneumococci may explain in part why pneumococci invade
the submucosa during nasal colonization.
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Fusion expression of bovine lactoferricin in
Escherichia Coli
Jianhua Wang, X. Feng, A. Shan, D. Teng, Y. Yao, Y. Shao, S. Liu, and F. Zhang
Gene Engineering Laboratory, Feed Research Institute, Chinese Academy of Agricultural
Sciences, Beijing 100081, China; Animal Nutrition Research Institute, Northeast
Agricultural University, Harbin 150030, China; Department of Pharmaceutical Science,
University of Toronto, Toronto, ON M5S 2S2, Canada; College of Food Science and
Technology, Huazhong Agricultural University, Wuhan 430070, China; College of Food
Science and Technology, Nanjing Agricultural University, Nanjing 210095, China
The drug-resistance problem has been growing with use
of current antibiotics in the feed and medical industries.
LfcinB, a 25 amino acid antibacterial peptide derived from
bovine lactoferrin, is a potential alternative to antibiotics.
According to the bias of codon use in Escherichia coli, the
gene encoding LfcinB has been chemically synthesized and
ligated into the expression vector pGEX-4T-2. The antibac-
terial peptide was fused with GST with a protease cleavage
site in between them. Two constructs with different cleavage
sites were made. One construct, GEX–Th–LCB, contained a
thrombin cleavage site provided by the vector. In the second
construct, GEX–Th–Xa–LfcinB, a factor Xa cleavage site
was introduced after the thrombin cleavage site. The GST–
Th–LCB protein was efficiently cleaved by thrombin and
the recombinant LfcinB showed antibacterial activity. How-
ever, the fusion protein containing the factor Xa recognition
site could not be cleaved by factor Xa in this study. The
high level of expression of LfcinB in E. coli provides a pos-
sible method for producing LfcinB in large amounts. This
project is funded by Chinese National Hi-Tech Research
and Development Program Nos. 2004AA246040 and
2003AA241160–01.
The efficacy of bovine lactoferrin and ifn-a 2b
combination therapy following 24-week regimen
of ribavirin plus ifn-a 2b for chronic hepatits C
patients infected with genotype 1b and high viral
load
K. Ishii, Y. Sumino, M. Kogame, K. Higami, M.I. Shinohara, K. Matsumaru,
M.A. Shinohara, H. Nagai, M. Watanabe, K. Miki, K. Yamauchi, and S. Teraguchi
Division of Gastroenterology and Hepatology, Toho University School of Medicine, Tokyo,
Japan; Nutritional Science Laboratory, Morinaga Milk Industry Co, Ltd, Kanagawa, Japan
The aim of this study was to clarify the efficacy of a regi-
men of oral bovine lactoferrin (bLF) and interferon-a 2b
(IFNa-2b) combination therapy following a 24 week course
of ribavirin plus IFN-a 2b for chronic hepatitis C (CHC) pa-
tients. Forty patients with biopsy-proven CHC who were in-
fected with genotype 1b and had a high viral load were
eligible for the study. Their baseline HCV-RNA quantified
by RT-PCR (Amplicor v. 2.0; Roche, Basel, Switzerland) in
serum was more than 101 KIU/mL. A 24 week regimen of
IFNa-2b (6 MU daily for 2 weeks, followed by 6 MU 3
times/week for 22 weeks) and ribavirin (daily dose of 600–
800 mg according to body mass) was given to all patients.
After week 24, 13 patients (a median baseline HCV-RNA
of 385 KIU/mL) were discontinued (control group), 13 pa-
tients (a median baseline HCV-RNA of 430 KIU/mL) were
given 600 mg/day of oral bLF (Lactoferrin activeR, Mori-
naga) and 3–6 MU IFNa-2b for a median period of 6 months
(bLf group), and the remaining 14 patients (a median base-
line HCV-RNA of 490 KIU/mL) were given 3–6 MU IFNa-
2b for a median period of 6 months (IFN group).
The negativity of serum HCV-RNA using a qualitative
method (Amplicor) at weeks 4, 12, and 24 was seen in 1, 3,
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and 4 patients from the control group; in 1, 3, and 6 patients
from the bLf group; and in 2, 6, and 8 patients from the IFN
group, respectively. Sustained viral response (serum HCV-
RNA at 24 weeks after the end of therapy was negative)
was seen in 1 patient from the control group, in 4 patients
from the bLf group, and in 2 patients from the IFN group.
These results indicate that bLF and IFNa-2b combination
therapy following a 24-week course of ribavirin plus IFNa-
2b is effective for CHC patients infected with genotype 1b
and a high viral load.
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